Cas:14913-33-8 trans-Dichlorodiamineplatinum(II) manufacturer & supplier

Chemical Name:trans-Dichlorodiamineplatinum(II)

CAS.NO:14913-33-8

Synonyms:trans–diamminedichloroplatinum(II);EINECS 238-980-9;trans-diamminodichloroplatinum(II);trans-diaminedichloroplatinum(II);UNII:Q20Q21Q62J;Dichloroplatinum diammoniate;trans-Platinum diammine dichloride;MFCD00011623;CIS-PLATIN;transplatin;trans-dichlorodiammineplatinum(II);trans-dichlorodiamine platinum(II);trans-Dichlorodiamineplatinum(II);Cisplatin impurity A;trans-Diamminedichloroplatinum(II) (trans-Dichlorodiammineplatinum(II);cis-Diamminedichlorplatine

Molecular Formula:H₆Cl₂N₂Pt

Molecular Weight:300.051

HS Code:

Physical and Chemical Properties:

Melting point:340ºC (dec.)

Boiling point:N/A

Density:3.746 g/cm3

Index of Refraction:1.706

PSA:6.48000

Exact Mass:298.955597

LogP:2.02430

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3288

Packing Group:II

Contact us for information like trans–diamminedichloroplatinum(II) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cis-Diamminedichlorplatine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,trans-dichlorodiamine platinum(II) Use and application,trans-Platinum diammine dichloride technical grade,usp/ep/jp grade.

Related News: he agency said the drugmaker and Emergent must agree that the FDA can share relevant information about the manufacturing of the doses with regulators where the vaccine is shipped. trans-Dichlorodiamineplatinum(II) manufacturer ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� trans-Dichlorodiamineplatinum(II) supplier Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. trans-Dichlorodiamineplatinum(II) vendor Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. trans-Dichlorodiamineplatinum(II) factory he agency said the drugmaker and Emergent must agree that the FDA can share relevant information about the manufacturing of the doses with regulators where the vaccine is shipped.